Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study

Background: Real-life data on the administration of letermovir as cytomegalovirus (CMV) primary prophylaxis after allogeneic hematopoietic cell transplantation (HCT) remain limited. Methods: We conducted a retrospective single-center matched cohort study, comparing consecutive high-risk allogeneic H...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Vaccines (Basel)
Autori principali: Royston, Léna, Royston, Eva, Masouridi-Levrat, Stavroula, Vernaz, Nathalie, Chalandon, Yves, Van Delden, Christian, Neofytos, Dionysios
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8069238/
https://ncbi.nlm.nih.gov/pubmed/33921218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/vaccines9040372
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi